In vivo assessment of triple agent thermo-responsive otic gels in patients with acute otitis externa. Phase 2 trial.
University of Queensland
30 participants
Sep 23, 2019
Interventional
Conditions
Summary
Otitis Externa (swimmers ear) is inflammation of the ear canal and leads to significant pain. The current treatment involves ear drops which are difficult to insert and requiring regular insertion. This leads to decreased patient compliance and a notably increasing level of antimicrobial resistance. This project involves the initial assessment of a newly created thermoresponsive ear gel (a gel that is drops at room temperature and changes to a gel a body temperature) in individuals with otitis externa. We hypothesis the ear gel will gelate in the ear canal, treating otitis externa and causing minimal adverse events.
Eligibility
Inclusion Criteria3
- o Aged between 18-60 years at time of recruitment
- o ASA 1-28 (healthy, non-smoker or with mild disease without substantive functional limitations)
- o Available for ongoing follow up and review
Exclusion Criteria7
- o Overt fungal otitis externa based on clinical examination
- o Congenital abnormality, obstructive exostoses or malignancy of the ear canal
- o Seborrheic dermatitis or other dermatological conditions of the affected external ear canal.
- o Known or suspected tympanic membrane perforation or tympanostomy tube
- o Known allergy or sensitivity to ciprofloxacin, quinolones, dexamethasone, corticosteroids or shell fish.
- o Patients who have an ASA 3 or more (severe systemic disease)8
- o Patients who are pregnant or lactating
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The patient will receive a single dose of 0.5ml of the thermoresponsive gel containing active ingredients ciprofloxacin 0.6% and dexamethasone 0.2%. This will be delivered by blunt needle and syringe to the ear canal. Patient review/follow up will occur on day 2, if no improvement is seen patients will be removed from the study and given alternative treatment. Further review will occur on day 5 and 12 review of patient symptoms, side effects and ear will occur to ensure patient safety. If the gel remains visible in the external auditory canal at day 12 review, aural toilet will be performed to remove any of the remaining gel. Patients will be contacted four weeks following cessation of treatment to ensure no recurrence or side effects have occurred.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12618001896268